產(chǎn)品名稱：Phospholipid Screen IgG/IgM ELISA 產(chǎn) 地：Demeditec 產(chǎn)品貨號：DE7470 產(chǎn)品規(guī)格：96 Tests 產(chǎn)品說明： Special remarks: The DEMEDITEC Anti-Phospholipid Screen IgG/IgM assay is a quantitative enzyme immunoassay (EIA) intended to screen for the presence of IgG and IgM class autoantibodies against Cardiolipin, Phosphatidyl Serine, Phosphatidyl Inositol and Phosphatidic acid in human serum or plasma as an aid in the diagnosis of an increased risk of thrombosis in patients with Systemic Lupus Erythematosus (SLE) or lupus-like disorders. The first study of anti-Phospholipid antibodies began in 1906, when Wasserman introduced a serological test for Syphilis. In 1942, the active component was found to be a phospholipid, which was designated Cardiolipin. In the 1950s it became clear that a number of people had positive tests for syphilis without any evidence of the disease. This phenomenon was referred to as the biological false positive serological test for syphilis. A high prevalence of autoimmune disorders, including systemic lupus erythematosus (SLE) and Sjögrens Syndrome occurred in this group of patients. The presence of circulating anticoagulants in patients with SLE was first documented in 1952 and was associated with increased risk of paradoxical Thrombosis in 1963. The term Lupus anticoagulant (LA), first used in 1972, is clearly a misnomer, because LA is more frequently encountered in patients without lupus and is associated with thrombosis rather than abnormal bleeding. During the last years it became clear that the optimal binding of anti-Phospholipid antibodies is depending on a cofactor termed b2-Glycoprotein I (apolipoprotein H) (b2GPI). b2GPI is a 50 kDa b2-globulin occurring in plasma at a level of 200 µg/ml. It has been found that b2-Glycoprotein I inhibits the intrinsic coagulation pathway and, therefore, it is involved in the regulation of blood coagulation. b2GPI is associated in vivo with negatively-charged substances, e.g. anionic phospholipids, heparin and lipoproteins. The phospholipid binding region is located on its fifth domain. Under the acronym "aPL" (anti-Phospholipid antibodies) antibodies against negatively-charged phospholipids, such as CL (Cardiolipin), LA (Lupus Anticoagulant), PS (Phosphatidyl Serine), PI (Phosphatidyl Inositol) and PA (Phosphatidic Acid) are summarised. Of these, Cardiolipin is the phospholipid most commonly used as antigen to test for aPL by ELISA. Some Antisera which bind cardiolipin-coated ELISA plates can also bind to plates coated with other negatively-charged phospholipids, such as Phosphatidyl Serine (PS), Phosphatidyl Inositol and Phosphatidic Acid (PA). Some investigators have suggested that the use of PS in place of cardiolipin in ELISA tests enables more specific diagnosis. These antigens are less commonly used and their additional use can improve the clinical sensitivity in patient samples with suspected APS (Anti-Phospholipid-Syndrome), but they can't replace the measurement of autoantibodies against Cardiolipin. 上海玉博生物技術(shù)有限公司在為生命科學(xué)領(lǐng)域提供豐富的產(chǎn)品與信息資源方面處于****地位，公司提供的產(chǎn)品涵蓋了二十多個國家近五十萬種產(chǎn)品，而且產(chǎn)品的數(shù)量與信息在不斷的增長和更新，公司提供的產(chǎn)品能夠使生命科學(xué)工作者加快對生物化學(xué)，分子生物學(xué)，細胞生物學(xué)以及蛋白質(zhì)組學(xué)研究的認知，以及分子診斷和臨床醫(yī)學(xué)領(lǐng)域的應(yīng)用。
滬公網(wǎng)安備 31011002002623號
